Fatty liver disease, now called MASLD when linked to metabolic risk factors, covers a range of disease. When liver fat comes with inflammation and cell injury, the diagnosis is MASH. The difference matters when assessing liver scarring in people with type 2 diabetes, because the treatment evidence here comes mainly from patients who already had MASH and measurable scarring [1][2].
What semaglutide improved in ESSENCE
The first 800 adults in the phase 3 trial had biopsy-confirmed MASH and stage F2 or F3 fibrosis. In the 72-week interim analysis, MASH resolved without worse scarring in 62.9% of those assigned weekly semaglutide 2.4 mg versus 34.3% on placebo (estimated difference 28.7 percentage points, 95% CI 21.1 to 36.2). Scarring improved by at least one stage without worsening MASH in 36.8% versus 22.4% (difference 14.4 percentage points, 95% CI 7.5 to 21.3) [1]. These biopsy results do not establish whether treatment prevents liver failure or extends life.
How tirzepatide and other drugs compare
The report on the experimental oral drug TERN-601 concerns a liver safety finding in a separate program. A liver safety signal and an improvement in MASH are different outcomes.
In the 52-week phase 2 SYNERGY-NASH trial, 190 adults with biopsy-confirmed MASH and F2–F3 fibrosis were randomized. MASH resolved without worse fibrosis in 44% to 62% across the three tirzepatide doses versus 10% on placebo [2]. The trial compared tirzepatide with placebo, so comparing these rates directly with ESSENCE would be misleading.
A network meta-analysis of 13 trials and 3,871 participants with fibrosis stages F1–F3 found evidence for MASH resolution without worse scarring with several interventions, including tirzepatide, investigational survodutide and resmetirom [3]. Its estimates combine direct and indirect comparisons, some with wide uncertainty. The analysis cannot reliably establish which drug offers the greatest benefit for the same patients.
What is approved in the United States?
The U.S. Wegovy injection label includes adults with noncirrhotic MASH and F2–F3 fibrosis. The FDA granted accelerated approval based on improvement in MASH and fibrosis[4]. Resmetirom (Rezdiffra), a tablet that acts on a thyroid hormone receptor, also has accelerated approval for this population [5]. A finding of liver fat alone does not meet either MASH indication.